Improved Exercise Tolerance After Losartan and Enalapril in Heart Failure
- 27 October 1998
- journal article
- clinical trial
- Published by Wolters Kluwer Health in Circulation
- Vol. 98 (17) , 1742-1749
- https://doi.org/10.1161/01.cir.98.17.1742
Abstract
Background —In congestive heart failure, fatigue-resistant, oxidative, slow type I fibers are decreased in leg skeletal muscle, contributing to exercise capacity (EC) limitation. The mechanisms by which ACE inhibitors and AII antagonists improve EC is still unclear. We tested the hypothesis that improvement in EC is related to changes in skeletal muscle composition toward type I fibers. Methods and Results —Eight patients with congestive heart failure, NYHA classes I through IV, were treated for 6 months with enalapril (E) 20 mg/d, and another 8 with losartan (L) 50 mg/d. EC was assessed with maximal cardiopulmonary exercise testing at baseline and after treatment. Myosin heavy chain (MHC) composition of the gastrocnemius was studied after electrophoretic separation of slow MHC1, fast oxidative MHC2a, and fast glycolytic MHC2b isoforms from needle microbiopsies obtained at baseline and after 6 months. EC improved in both groups. Peak V̇ o 2 increased from 21.0±4.7 to 27.6±4.3 mL · kg −1 · min −1 ( P =0.011) in the L group and from 17.5±5.0 to 25.0±5.5 mL · kg −1 · min −1 ( P =0.014) in the E group. Similarly, ventilatory threshold changed from 15.0±4.0 to 19.9±4.9 mL ( P =0.049) with L and from 12.0±1.9 to 15.4±3.5 mL ( P =0.039) with E. MCH1 increased from 61.2±11.2% to 75.4±7.6% with L ( P =0.012) and from 60.6±13.1% to 80.1±10.9% ( P =0.006) with E. Similarly, MHC2a decreased from 21.20±9.5% to 12.9±4.4% ( P =0.05) with L and from 19.9±7.8% to 11.8±7.9% ( P =0.06) with E. MHC2b changed from 17.5±6.5% to 11.7±5.2% ( P =0.07) with L and from 19.5±6.4% to 8.1±4.6% ( P =0.0015) with E. There was a significant correlation between net changes in MHC1 and absolute changes in peak V̇ o 2 ( r 2 =0.29, P =0.029) and a trend to significance for MHC2a and 2b. Conclusions —Six months’ treatment with L and with E produces an improvement in EC of similar magnitude. These changes are accompanied by a reshift of MHCs of leg skeletal muscle toward the slow, more fatigue-resistant isoforms. Magnitude of MHC1 changes correlates with the net peak V̇ o 2 gain, which suggests that improved EC may be caused by favorable biochemical changes occurring in the skeletal muscle.Keywords
This publication has 41 references indexed in Scilit:
- Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE)Published by Elsevier ,1997
- Angiotensin II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism.Journal of Clinical Investigation, 1996
- Detection of abnormal calf muscle metabolism in patients with heart failure using phosphorus-31 nuclear magnetic resonanceThe American Journal of Cardiology, 1988
- Abnormalities of skeletal muscle in patients with chronic heart failureInternational Journal of Cardiology, 1988
- 31P nuclear magnetic resonance evidence of abnormal skeletal muscle metabolism in patients with congestive heart failureThe American Journal of Cardiology, 1987
- Exercise ventilation and pulmonary artery wedge pressure in chronic stable congestive heart failureThe American Journal of Cardiology, 1986
- Evaluation of energy metabolism in skeletal muscle of patients with heart failure with gated phosphorus-31 nuclear magnetic resonance.Circulation, 1985
- Exercise intolerance in patients with chronic heart failure: role of impaired nutritive flow to skeletal muscle.Circulation, 1984
- A sensitive SDS-page method separating myosin heavy chain isoforms of rat skeletal muscles reveals the heterogeneous nature of the embryonic myosinBiochemical and Biophysical Research Communications, 1983
- Significance of skeletal muscle oxidative enzyme enhancement with endurance trainingClinical Physiology and Functional Imaging, 1982